Skip to main content
. 2017 Nov 7;8:802. doi: 10.3389/fphar.2017.00802

FIGURE 5.

FIGURE 5

Caspase activation by AD0157 in human myeloid leukemia cells. (A) Effect of AD0157 on caspase-8, (B) caspase-9 and (C) caspase-3, -7 in HL60, U937 and KU812F. The determination of caspase-8, -9 and -3/-7 activities were carried out after leukemia cell treatment with AD0157 or vehicle for 6 h, 30 min and 14 h, respectively. Afterward, Caspase-Glo® 8, Caspase-Glo® 9 and Caspase-Glo® 3/7 reagents were added and the luminescence was recorded at 30 min. Treatment with 10 μM 2-methoxyestradiol (2ME) was used as a positive control. Data of caspase activities are expressed in arbitrary units ± SD of three independent assays with 3 replicates each one. ∗p < 0.05, #p < 0.005, and ∗∗p < 0.001 versus control. (D) Percentage of subG1 population (apoptotic cells) after pre-treatment for 2 h with either caspase-8 inhibitor Z-IETD-FMK, caspase-9 inhibitor Z-LEHD-FMK or pan caspase inhibitor Z-VAD-FMK, followed by AD0157 5 μM treatment for 14 h and flow cytometric analyses. Data are expressed as means ± SD of three independent experiments. ΨP < 0.005 versus untreated controls. ∗p < 0.05 and #p < 0.005 versus cells treated with AD0157 5 μM in absence of caspase inhibitors.